In female mice with DSS-induced colitis, orally administered Madecassic acid decreased the Th17/Treg cell ratio to 0.46 and 0.34 at 12.5, 25 mg/kg, respectively, versus the DSS group. Another study in female mice with DSS-induced colitis reported reduced colonic IL-17 expression following Madecassic acid treatment versus the DSS group. In male mice receiving a high-fat diet, intraperitoneal Madecassic acid restored acetylcholine-induced relaxation in aortic segments compared with HF-C. [1,2,3]
Th17/Treg Cell Ratio in DSS-Induced Colitis
Animal study · Female C57BL/6 mice; DSS-induced colitis; n=5–8 [1]
Female mice with DSS-induced colitis received Madecassic acid orally at 12.5, 25 mg/kg daily for 10 days. Compared with the DSS group, the Th17/Treg cell ratio decreased to 0.46 and 0.34, respectively.
Conditions shared by the study groups
- Route
- orally administered
- Treatment course
- daily for 10 days
- Vehicle
- 0.5% sodium carboxy methyl cellulose (CMC-Na)
- Madecassic acid 12.5, 25 mg/kg
- Model: Female C57BL/6 mice; DSS-induced colitis; n=5–8
Methods and source locations
Compound reported in the paper: Madecassic acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Madecassic acid restored the Th17/Treg balance in mice with DSS-induced colitis (S12, S13); Materials and methods > Reagents (S69); Materials and methods > Animals (S89); Materials and methods > Induction and assessment of DSS-induced colitis and drug administration (S92); Materials and methods > Intracellular staining and flow cytometry (S111, S112); Figure 1 legend (S146); Figure 2 legend (S160, S161, S162, S171)
ratio of Th17/Treg cells: ratio of Th17/Treg cells; comparator: DSS group — Results > Madecassic acid restored the Th17/Treg balance in mice with DSS-induced colitis (S12, S13)
Madecassic acid 12.5, 25 mg/kg · Results > Madecassic acid restored the Th17/Treg balance in mice with DSS-induced colitis (S13); Materials and methods > Induction and assessment of DSS-induced colitis and drug administration (S92); Figure 2 legend (S162)
Colonic IL-17 Expression in DSS-Induced Colitis
Animal study · female C57BL/6 mice; DSS-induced colitis; six mice per group [2]
In female mice with DSS-induced colitis, Madecassic acid orally gavaged at 25 mg/kg daily for 10 days reduced IL-17 expression in colon tissues versus the DSS group.
Conditions shared by the study groups
- Route
- orally gavaged
- Treatment course
- daily for 10 days
- Vehicle
- carboxyl methyl cellulose sodium (CMC-Na, 0.5%)
- Madecassic acid 25 mg/kg
- Model: female C57BL/6 mice; DSS-induced colitis; six mice per group
Methods and source locations
Compound reported in the paper: Madecassic acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > γδT17 cells are the main target cells of MA for reducing the expression of IL-17 in the colon of colitis mice (S6); Materials and methods > DSS-induced colitis in mice (S88, S89); Fig. 1 legend (S151, S153); Fig. 7 legend (S167)
expression of IL-17 in colon tissues: expression of IL-17 in colon tissues; comparator: DSS group — Results > γδT17 cells are the main target cells of MA for reducing the expression of IL-17 in the colon of colitis mice (S6)
Madecassic acid 25 mg/kg · Results > γδT17 cells are the main target cells of MA for reducing the expression of IL-17 in the colon of colitis mice (S6); Materials and methods > DSS-induced colitis in mice (S89)
Acetylcholine-Induced Relaxation in Aortic Segments
Animal study · male C57BL/6 J mice; aortic segments from HF mice [3]
In aortic segments from male mice fed a high-fat diet, Madecassic acid administered intraperitoneally at 20 mg/kg daily for 4 weeks restored acetylcholine-induced relaxation compared with HF-C.
Conditions shared by the study groups
- Route
- intraperitoneally (i.p)
- Treatment course
- daily; 4 weeks
- Vehicle
- saline with 1% DMSO
- Madecassic acid 20 mg/kg
- Model: male C57BL/6 J mice; aortic segments from HF mice
- Reported limits: Removed after verification: value.
Methods and source locations
Compound reported in the paper: Madecassic acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Animals and dietary treatments (S1, S2, S4, S5); Materials and Methods > Vascular reactivity in isolated aortic arteries cleaned of PVAT (S33, S35); Results > Treatment with EAE or MA improved endothelial function in HF mice (S90, S91); Table 2 legend (S145); Table 2 (T2.h1, T2.r1)
Emax ACh: Emax ACh; comparator: HF-C — Results > Treatment with EAE or MA improved endothelial function in HF mice (S91); Table 2 legend (S145); Table 2 (T2.h1, T2.r1)
Madecassic acid 20 mg/kg · Materials and Methods > Animals and dietary treatments (S4, S5); Results > Treatment with EAE or MA improved endothelial function in HF mice (S91); Table 2 legend (S145); Table 2 (T2.h1, T2.r1)